CapsoVision (NASDAQ:CV) and NeuroPace (NASDAQ:NPCE) Critical ContrastDefense World · Oct 2, 2026
Bank of America Corp DE Sells 145,741 Shares of NeuroPace, Inc. $NPCEDefense World · Sep 11, 2026
Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?Zacks Investment Research · Sep 10, 2026
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for NowZacks Investment Research · Sep 4, 2026
2,477,603 Shares in NeuroPace, Inc. $NPCE Bought by BlackRock Inc.Defense World · Sep 2, 2026
NeuroPace to Participate in 2026 Cantor Global Healthcare ConferenceBusiness Wire · Sep 1, 2026NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.22 | -$0.18 | Beat |
| May 12, 2026 | -$0.19 | -$0.20 | Miss |
| Mar 3, 2026 | -$0.14 | -$0.08 | Beat |
| Nov 4, 2025 | -$0.20 | -$0.11 | Beat |
| Aug 12, 2025 | -$0.24 | -$0.26 | Miss |
| May 13, 2025 | -$0.26 | -$0.21 | Beat |